Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of the American College of Cardiology|March 18, 2025
Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With CardiomyopathyFarooq H Sheikh, Gilbert Habib, W H Wilson Tang, et al.European Journal of Heart Failure|March 29, 2026
Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B studyYasuhiro Hamatani, Brian L Claggett, Muthiah Vaduganathan, et al.Journal of the American College of Cardiology|March 18, 2025
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With CardiomyopathyMathew S Maurer, Ronald M Witteles, Pablo Garcia-Pavia, et al.Neurology and Therapy|July 31, 2023
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with PolyneuropathyLaura Obici, Senda Ajroud-Driss, Kon-Ping Lin, et al.Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 1, 2026
Development and validation of the modified-comprehensive Kumamoto Score: a multi-organ assessment tool for hereditary transthyretin amyloidosisShiori Yamakawa, Toshiya Nomura, Yohei Misumi, et al.Neurology|October 22, 2020
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated AmyloidosisSimina Ticau, Gautham V Sridharan, Shira Tsour, et al.Journal of Neurology|November 16, 2019
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.Journal of Neurology|February 8, 2020
Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.Scientific Reports|June 3, 2021
Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestryMargaret M Parker, Scott M Damrauer, Catherine Tcheandjieu, et al.The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.Pageof 2